For decades, a daily low-dose aspirin was treated as a nearly universal recommendation for older adults hoping to ward off a heart attack or stroke. That advice has been substantially narrowed. Following a review of updated clinical trial evidence, the nation’s leading preventive medicine panel now says most healthy older adults should not start taking daily aspirin at all, reversing guidance that shaped medicine cabinets for a generation.
Why The Old Blanket Advice Fell Out Of Favor
The shift traces to newer, larger clinical trials that measured aspirin’s effects in adults who had never had a heart attack or stroke, rather than in those managing existing heart disease. Those trials found that aspirin’s ability to prevent a first cardiovascular event was smaller than earlier data suggested, while its tendency to cause internal bleeding, including gastrointestinal bleeding and hemorrhagic stroke, remained a real and sometimes serious risk, one that increases with age. That recalculated balance of benefit and harm is what prompted the U.S. Preventive Services Task Force to revisit its guidance.
Earlier recommendations, some dating back more than 20 years, had been based on trial data collected before statins, blood pressure medications, and smoking-cessation treatment became as widespread as they are now. As those other tools lowered baseline cardiovascular risk across the population, aspirin’s added benefit for someone without existing heart disease shrank, even as the bleeding risk stayed essentially the same.
What The Current Guidance Says By Age
In 2022, the U.S. Preventive Services Task Force issued a “D” recommendation against starting low-dose aspirin for primary prevention of cardiovascular disease in adults 60 and older, its strongest form of guidance against a practice. For adults ages 40 to 59 who have a 10% or greater estimated 10-year cardiovascular risk and no elevated bleeding risk, the task force issued a “C” recommendation, meaning the decision should be individualized through a conversation between patient and clinician rather than applied as a blanket rule. The task force’s language marks a formal narrowing of a recommendation that, in earlier decades, had been extended much more broadly across the older adult population.
The Trial That Changed The Calculation
A major driver of the reassessment was ASPREE, short for Aspirin in Reducing Events in the Elderly, a large randomized trial that followed healthy adults age 70 and older, most of whom had no history of cardiovascular disease. Published in 2018, the trial found that daily low-dose aspirin did not extend disease-free survival in that population and was associated with a higher rate of major bleeding, including bleeding in the brain and gastrointestinal tract, than placebo. The trial also found a higher rate of death among aspirin users, a result researchers have continued to study and debate, though it reinforced the broader pattern showing little net benefit for healthy older adults with no prior cardiovascular event.
Earlier interest in daily aspirin had also been fueled by observational research suggesting a possible reduced risk of colorectal cancer among long-term users, a benefit that takes years to appear and that the task force said does not, on its own, outweigh the bleeding risk for most adults starting aspirin purely for that reason.
How Cardiology Groups Responded
The American College of Cardiology noted that the revised guidance applies specifically to primary prevention, meaning people who have not yet had a cardiovascular event, and does not change long-standing advice for secondary prevention. Physicians reviewing the update have generally aligned with the task force’s framing: aspirin still meaningfully reduces cardiovascular events in trials, but for people without existing heart disease, the added bleeding risk now outweighs that benefit for most people once age-related bleeding risk rises, particularly past 60.
Why Aspirin Is Different After A Heart Attack Or Stroke
None of the revised guidance applies to people who have already had a heart attack, ischemic stroke, or have documented coronary artery disease. For that group, known in clinical terms as secondary prevention, daily low-dose aspirin remains standard, well-supported therapy, since the calculation of benefit versus bleeding risk is different once a person has already shown they are prone to clot-related cardiovascular events. Patients in this category who are currently taking aspirin on a doctor’s recommendation are not the population the newer guidance is asking clinicians to reconsider.
What The Change Means For Someone Already Taking It
The task force and cardiology groups have both emphasized that the update is not a directive for current users to stop cold. Aspirin has been used as a cardiovascular preventive medication for decades, and stopping it abruptly carries its own, separate considerations for people managing existing risk factors, particularly those who began taking it years ago for reasons a newer doctor may not have fully reviewed. Clinicians reweighing a patient’s aspirin regimen typically start by asking whether it was originally prescribed for primary or secondary prevention, then weigh current age and bleeding history before recommending any change, which is why medical groups have consistently framed the update as guidance for a conversation with a doctor rather than a rule to apply without medical input.
This article was produced with the assistance of AI and reviewed by Morning Overview editors.
More from Morning Overview
